Menu

High-Profile Diabetes Study Retracted

The results, which could not be replicated, suggested that a hormone increased pancreatic β cell proliferation, supplanting insulin as a front-line diabetes treatment in mice.

Dec 28, 2016
Joshua A. Krisch

PIXABAY, STEVEPBIn 2013, Harvard University stem cell researcher Douglas Melton and colleagues described an innovative diabetes treatment that “could augment or replace insulin injections,” they wrote in a study published in Cell. The authors demonstrated that a hormone called betatrophin, or Angiopoietin-like protein 8 (Angptl8), could ramp up pancreatic β cell proliferation in mice, combatting insulin resistance.

But after multiple failed attempts to replicate the findings—and one study by Melton himself, published in PLOS ONECell has retracted the paper. “I wanted to make sure anyone doing a PubMed search would see this is our present view,” Melton told Retraction Watch. “It would be most unfortunate if a lab missed the PLOS ONE paper, then wasted time and effort trying to replicate our results.”

The once promising results began to unravel in 2014, when an independent team of researchers at Regeneron Pharmaceuticals published a paper in Cell that found Angptl8 did not influence β cell expansion. But then in 2015, researchers managed to replicate Melton’s findings in rats.

See “Diabetes 'Breakthrough' Breaks Up

Melton ultimately enlisted two other labs to help conduct a blinded experiment to determine whether his initial findings were correct. The initiative resulted in a PLOS ONE study in July 2016 that concluded that “the original paper describing the betatrophin hypothesis needs to be withdrawn.”

“It’s an example of how scientists can work together when they disagree, and come together to move the field forward,” Melton told Retraction Watch. “The history of science shows it is not a linear path.”

April 2019

Will Car T Cells Smash Tumors?

New trials take the therapy beyond the blood

Marketplace

Sponsored Product Updates

Getting More Consistent Results by Knowing the Quality of Your Protein
Getting More Consistent Results by Knowing the Quality of Your Protein
Download this guide from NanoTemper to learn how to identify and evaluate the quality of your protein samples!
Myth Busting: The Best Way to Use Pure Water in the Lab
Myth Busting: The Best Way to Use Pure Water in the Lab
Download this white paper from ELGA LabWater to learn about the role of pure water in the laboratory and the advantages of in-house water purification!
Shimadzu's New Nexera UHPLC Series with AI and IoT Enhancements Sets Industry Standard for Intelligence, Efficiency and Design
Shimadzu's New Nexera UHPLC Series with AI and IoT Enhancements Sets Industry Standard for Intelligence, Efficiency and Design
Shimadzu Corporation announces the release of the Nexera Ultra High-Performance Liquid Chromatograph series, incorporating artificial intelligence as Analytical Intelligence, allowing systems to detect and resolve issues automatically. The Nexera series makes lab management simple by integrating IoT and device networking, enabling users to easily review instrument status, optimize resource allocation, and achieve higher throughput.
IDT lowers genomic barriers with powerful rhAmpSeq™ targeted sequencing system
IDT lowers genomic barriers with powerful rhAmpSeq™ targeted sequencing system
Increasing accuracy and reducing cost barriers, IDT’s innovative system delivers simple and cost-effective amplicon sequencing